Core Viewpoint - Morgan Stanley has downgraded the profit forecast for China Traditional Chinese Medicine from 2025 to 2030 by 10% to 14%, reflecting increased impairment provisions related to the price reduction of Chinese medicine formula granules [1] Group 1: Financial Performance - The target price has been reduced from HKD 1.6 to HKD 1.5, maintaining a "reduce" rating [1] - The company's performance continues to fall short of market expectations, and the quality of earnings has declined [1] Group 2: Investor Sentiment - The termination of a highly publicized transaction last year may negatively impact investors' perception of the company's governance [1] - Ongoing selling pressure on the stock is anticipated, as event-driven investors are likely to continue reducing their remaining holdings [1]

Core Insights - The conference focused on "Brand Leadership, Technological Empowerment, and Promoting High-Quality Development" in the traditional Chinese medicine (TCM) industry, gathering over 700 participants from various sectors to discuss innovation and development strategies [1][2] Group 1: Conference Highlights - The China Traditional Chinese Medicine Association launched a quality technology platform for the entire TCM industry chain, aiming to enhance quality control and industry resilience [2] - The conference featured keynote speeches from experts discussing innovation in TCM and regulatory practices, emphasizing the integration of traditional and modern medicine [2][3] - Several reports were released, including the "China TCM Decoction Piece Industry Development Report (2024-2025)" and the "China Ganoderma Industry Development Report," showcasing advancements and research in the field [3] Group 2: Achievements and Future Directions - The China Traditional Chinese Medicine Association celebrated its 25th anniversary, highlighting its commitment to serving the industry and promoting sustainable use of TCM resources [4] - The association aims to strengthen its professional, platform-based, and digital service capabilities to support the modernization and internationalization of the TCM industry [4] - Future initiatives will focus on enhancing the quality and efficiency of the entire TCM industry chain, aligning with national health strategies and the demand for TCM [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 香港，2025年12月19日 於本公告日期，董事會由十二名董事組成，其中楊軍先生、李鴻堅先生及彭力先生為執 行董事；劉海建先生、李向榮先生、祖敬先生、許京輝女士及黃灝先生為非執行董事； 及謝榮先生、余梓山先生、秦嶺先生及李偉東先生為獨立非執行董事。 570 由於本公司需要更多時間編製及落實該通函所載之若干資料，預期該通函的寄發日期將 延遲至2026年1月15日或之前。 承董事會命 中國中藥控股有限公司 主席 楊軍 延遲寄發通函 茲提述中國中藥控股有限公司（「本公司」）日期為2025年11月25日之公告，內容有關更新 持續關連交易（「該公告」）。除另有界定者外，本公告所用詞彙與該公告所界定者具相同 涵義。 如該公告所披露，一份載有（其中包括）(i)該等協議及其各自項下擬進行之交易之詳情； (ii ...

Core Viewpoint - The Hong Kong government has officially released the "Traditional Chinese Medicine Development Blueprint," which aims to promote comprehensive, high-quality, and high-level development of traditional Chinese medicine (TCM) in Hong Kong [1][2] Group 1: Development Goals - The blueprint includes eight goals, such as optimizing clinical services, establishing a cross-professional service system, and leading the development of TCM professionals [1][2] - Goals also focus on enhancing the quality of Chinese medicine, establishing international standards, driving research and innovation, promoting TCM culture, and facilitating the global outreach of TCM services [2] Group 2: Industry Outlook - CITIC Securities indicates that the short-term pressure on the Chinese medicine industry is expected to ease, with channel inventory clearing accelerating and demand expected to recover by year-end [1][3] - Huajin Securities emphasizes the importance of the "premium + innovation" strategy in the Chinese medicine sector, highlighting the strong brand effect and pricing power of premium Chinese medicine products [3] Group 3: Company Highlights - China Traditional Chinese Medicine (00570) reported a revenue of approximately 7.46 billion RMB for the first half of 2025, a year-on-year decrease of 11.0%, with a gross profit of about 3.63 billion RMB, down 10.5% [5] - Tong Ren Tang (03613) is a historic brand in the Chinese medicine industry, producing over 400 types of traditional Chinese medicine products [6] - Guo Sheng Tang (02273) is actively expanding its presence in Singapore through a strategy of mergers, partnerships, and self-built initiatives [6] - Baiyunshan (00874) reported a revenue of 61.606 billion RMB for the first three quarters of 2025, an increase of 4.31% year-on-year, with a net profit of 3.31 billion RMB, up 4.78% [6]

Core Viewpoint - The Hong Kong government has officially released the "Traditional Chinese Medicine Development Blueprint," aiming to promote comprehensive, high-quality, and high-level development of traditional Chinese medicine (TCM) in Hong Kong, encompassing five areas, eight goals, and twenty actions [1][2]. Group 1: Development Goals - The eight goals include optimizing clinical services, establishing a cross-professional service system, leading the development of TCM professions, enhancing the quality of TCM, building international standards for TCM, driving research and innovation in the industry, promoting TCM culture, and facilitating the global outreach of TCM [1][2]. - The government aims to enhance the quality of TCM services and integrate them into the healthcare system, thereby improving public health and establishing Hong Kong as a bridge for TCM to the world [2][3]. Group 2: Industry Outlook - CITIC Securities indicates that the short-term pressure on the TCM industry is expected to ease, with channel inventory clearing accelerating, and anticipates a demand rebound by year-end, along with opportunities for fundamental and valuation improvements [1][3]. - Huajin Securities emphasizes the importance of the "premium + innovation" strategy in the TCM sector, highlighting that premium TCM products possess significant medical value and consumer attributes, while innovative TCM is gradually entering a harvest period supported by favorable policies [3][4]. Group 3: Company Highlights - China Traditional Chinese Medicine (00570) reported a revenue of approximately 7.46 billion RMB for the first half of 2025, a year-on-year decrease of 11.0%, with a gross profit of about 3.63 billion RMB, down 10.5%, but with a gross margin of 48.7%, up 0.3 percentage points from the previous year [5]. - Tong Ren Tang (03613), a historic brand in the TCM industry, produces over 400 types of traditional Chinese medicine, covering various medical fields [5][6]. - Guo Sheng Tang (02273) is actively expanding its TCM services in Singapore through a strategy of mergers, partnerships, and self-built initiatives, including a recent joint venture with a digital healthcare platform [6]. - Baiyunshan (00874) reported a revenue of 61.606 billion RMB for the first three quarters of 2025, an increase of 4.31% year-on-year, with a net profit of 3.31 billion RMB, up 4.78% [6].

证券之星消息，12月17日南向资金增持139.8万股中国中药（00570.HK）。近5个交易日中，获南向资金 增持的有4天，累计净增持1207.0万股。近20个交易日中，获南向资金增持的有11天，累计净增持1437.0 万股。截至目前，南向资金持有中国中药（00570.HK）15.94亿股，占公司已发行普通股的31.64%。 中国中药控股有限公司是一家主要从事中药制造及销售的投资控股公司。该公司通过四个分部运营业 务。一方分部主要从事中药配方颗粒、中药大健康产品及中药饮片的生产及销售。天江分部主要从事中 药配方颗粒、中药饮片及中药大健康产品的生产及销售。该分部还透过其线下医疗机构提供中医药相关 的医疗保健解决方案,包括中医问诊诊断、中医理疗、中药配方颗粒处方药等产品。同济堂分部主要从 事中药配方颗粒、中药饮片及中成药的生产及销售。该分部还从事大健康产业的各种大健康产品的生产 及销售及透过线下医疗机构提供中药医疗保健解决方案。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

《澳大利亚人》报15日报道说，力拓集团已放弃西澳大利亚大片土地的勘探权，在新首席执行官西蒙· 特罗特（Simon Trott）领导下，该公司正大幅缩减其锂业务愿景。 此外，在多年许可受阻和当地反对之后，力拓已将塞尔维亚的贾达尔（Jadar）锂项目搁置。 力拓公司越来越清晰地表明，澳大利亚不在其锂业务未来的规划之中，其战略重点已转向阿根廷，其次 是南美洲其他国家以及加拿大。 西澳拥有全球领先的硬岩锂矿，但上周力拓向市场阐述其战略时并未提及该地区。公司最终只会运营一 座锂辉石矿，该矿位于加拿大，旨在为魁北克的贝坎库尔（Bécancour）精炼厂提供原料。至于是加拿 大的哪座矿，力拓将在霍布奇（Whabouchi）项目和银河（Galaxy）项目之间做出选择。这两个项目均 已完成详细设计和前期场地工程，预计两年内可投产，合计年产能超过50万吨。 力拓锂业务负责人贾贝尔·贝拉布迪（Djaber Belabdi）表示，公司优先发展的是阿根廷的卤水提锂项 目，采用标准化的直接提锂（DLE）技术。 据报道，力拓已放弃对西澳近15万公顷土地的控制权，并准备出售已停产的卡特林山（Mt Cattlin）锂 矿，这是特罗特改善公司投 ...

相关报告：智研咨询发布的《2026-2032年中国中药材行业市场全景评估及发展趋势研究报告》 根据中国海关数据显示：2025年10月中国中药材进口数量为1.13万吨，同比下降38.1%，进口金额为 0.17亿美元，同比下降47.4%，2025年10月中国中药材出口数量为1万吨，同比增长6.1%，出口金额为 0.75亿美元，同比增长10%。 近一年中国中药材进口情况统计图 近一年中国中药材出口情况统计图 数据来源：中国海关，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 数据来源：中国海关，智研咨询整理 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 中國中藥控股有限公司 | | | 呈交日期: | 2025年12月3日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00570 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 5,035,801,852 | | 0 | | 5,035,801,852 | | 增加 / 減少 (-) | | | | ...

证券之星消息，12月1日南向资金减持391.6万股中国中药（00570.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持61.8万股。近20个交易日中，获南向资金减持的有11天，累计净减持270.6万 股。截至目前，南向资金持有中国中药（00570.HK）15.87亿股，占公司已发行普通股的31.51%。 中国中药控股有限公司是一家主要从事中药制造及销售的投资控股公司。该公司通过四个分部运营业 务。一方分部主要从事中药配方颗粒、中药大健康产品及中药饮片的生产及销售。天江分部主要从事中 药配方颗粒、中药饮片及中药大健康产品的生产及销售。该分部还透过其线下医疗机构提供中医药相关 的医疗保健解决方案,包括中医问诊诊断、中医理疗、中药配方颗粒处方药等产品。同济堂分部主要从 事中药配方颗粒、中药饮片及中成药的生产及销售。该分部还从事大健康产业的各种大健康产品的生产 及销售及透过线下医疗机构提供中药医疗保健解决方案。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | ...